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Reinforcing defective tolerogenic processes slows progression of autoimmune (AI)
diseases and has potential to promote drug-free disease remission. Previously,
we reported that DNA nanoparticles (DNPs) and cyclic dinucleotides (CDNs) slow
progression of experimental autoimmune encephalomyelitis (EAE), a mouse model of
multiple sclerosis, by activating the Stimulator of Interferon Genes (STING) signaling
adaptor to stimulate interferon type 1 (IFN-I) production, which induced dendritic cells to
express indoleamine 2,3 dioxygenase (IDO) and acquire immune regulatory phenotypes.
Here, we show that therapeutic responses to DNPs depend on DNA sensing via
cyclic GAMP synthase (cGAS) and interactions between Programmed Death-1 (PD-1)
and PD-1 ligands. To investigate how increased tryptophan (Trp) metabolism by IDO
promotes therapeutic responses mice were co-treated at EAE onset with DNPs and
drugs that inhibit kynurenine aminotransferase-II (KatII) or 3-hydroxyanthranilic acid
dioxygenase (HAAO) activity downstream of IDO in the kynurenine (Kyn) pathway.
DNP and KatII or HAAO inhibitor co-treatments suppressed EAE progression more
effectively than DNPs, while KatII inhibition had no significant therapeutic benefit and
HAAO inhibition attenuated but did not prevent EAE progression. Moreover, therapeutic
responses to co-treatments were durable as EAE progression did not resume after
co-treatment. Thus, using STING agonists to boost IDO activity andmanipulating the Kyn
pathway downstream of IDO is an effective strategy to enhance tolerogenic responses
that overcome autoimmunity to suppress EAE progression.
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INTRODUCTION
Sustained interferon type I (IFN-I) production by activated
dendritic cells (DCs) is widely regarded as a common driver
of autoimmune (AI) syndromes in humans and mice (1).
Under aseptic conditions, some DCs produce IFN-I when they
sense damage associated molecular patterns (DAMPs) such
as DNA. A critical role for tissue DNA as an autoimmune
trigger emerged in mice lacking DNA catabolizing enzymes,
which succumbed to spontaneous, lethal autoimmunity due to
sustained cytosolic DNA sensing to activate the signaling adaptor
Stimulator of Interferon Genes (STING), a potent IFNβ inducer
(2, 3). The paradigm that DNA sensors incite immunity via
STING/IFN-I signaling was also reinforced by reports showing
that cyclic dinucleotides (CDNs), which bind and activate
STING, incited robust anti-tumor immunity (4). Consequently,
STING agonists have emerged as promising adjuvants to treat
infections and cancer.
On the other hand, IFN-I also induces specialized DC
subsets to express indoleamine 2,3 dioxygenase (IDO), which
acquire potent T cell regulatory functions due to increased
tryptophan (Trp) metabolism (5). IDO activity is commonly
elevated at sites of chronic inflammation associated with AI
disease, suggesting that IFN-I signaling may have diametric roles
in regulating, as well as promoting autoimmunity. Consistent
with this paradigm, STING/IFN-I signaling slowed autoimmune
lupus disease progression in susceptible MRLlpr mice and
promoted tumor growth (6–8).Moreover, cargoDNA released by
DNA nanoparticles (DNPs) and CDNs alleviated experimentally
induced autoimmune encephalitis (EAE) and arthritis in mice
by stimulating STING/IFN-I signaling to induce IDO1 gene
expression (9, 10). Increased IDO activity suppresses immunity
by depleting tryptophan (Trp) to activate GCN2 stress responses
and generating immune suppressive Trp metabolites, some of
which stimulate aryl hydrocarbon receptor (AhR) signaling
(11). Therapeutic responses to DNPs and apoptotic cells were
dependent on STING/IFN-I signaling to induce IDO in specific
DC subsets to suppress effector T cell responses (12). Thus,
STING/IFN-I signaling incites diametric immune responses in
distinct settings of disease and therapy. Here we show that
therapeutic responses to DNPs in the EAE model depend on
the cytosolic DNA sensor cGAS and the PD-1/PD-L pathway.
Moreover, DNP treatments to activate STING were more
effective and durable when combined with drugs that modify Trp
metabolism downstream of IDO.
MATERIALS AND METHODS
Mice and Induction of EAE
C57BL/6J (B6) and PD1-deficient (PD1-KO) mice were obtained
from Jackson Laboratories, PD-L2-KO, PD-L1/2-KOwere kindly
provided by Arlene Sharpe (Harvard Medical School, MA, USA)
and cGAS-KO mice were kindly provided by Herbert (Skip)
Virgin (Washington University, St. Louis, MO). Mice were bred
under specific pathogen-free conditions at Augusta University,
USA or at Newcastle University, UK. ARRIVE guidelines were
followed to minimize the number of animals used.
EAE Induction and Treatments
To induce EAE, mice (age 8–12 wk) were immunized at two sites
on rear flanks with myelin oligodendrocyte glycoprotein peptide
MEVGWYRSPFSRVVHLYRNGK (MOG35−55; 100 µg, s/c, Bio
Basic Canada) emulsified in CFA (Difco Laboratories, Detroit,
MI) containing 4 mg/ml Mycobacterium tuberculosis H37Ra
(Difco Laboratories). Pertussis toxin (PTX, 200 ng; Sigma-
Aldrich) was given (i/p) on days 0 and 2 after immunization.
Clinical symptoms of EAE were scored on a scale from 0
to 5 as follows: 0, no clinical signs; 0.5, partial limp tail; 1,
full limp tail or waddling gait; 1.5, limp tail and waddling
gait/lumbar weakness; 2, partial paralysis of one hindlimb;
2.5, paralysis of one hindlimb or partial paralysis of both
hindlimbs; 3, paralysis of one hindlimb and partial paralysis
of the other hindlimb; 4, paralysis of both hindlimbs; 5,
complete paralysis of both hindlimbs and weakness of the
upper limb/three paralyzed limbs/moribund state (>20% weight
loss and/or complete hind paralysis with hyperventilation
and urinary incontinence) or dead. By disease onset groups
of mice received intravenous injections of DNPs (prepared
by mixing 7 µl of 150mM linear polyethylenimine, PEI,
from Sigma, with 21 µg CpGfree LacZ pDNA in 200 µl
5% glucose solution, N/P = 16.7), or cyclic guanylate (2′,5′)
monophosphate/adenosine (3′,5′) monophosphate (cGAMP;
Invivogen; 100 µg/200 ul saline) or vehicle treatments. Some
mice received the following drugs; Kat II inhibitor, PF-
04859989 (Sigma, given daily from day 11–22, 40 mg/kg, i/p),
AhR inhibitor CH-223191 (Sigma; 5 mg/kg, i/p given 1 h
before each cGAMP injection), HAAO inhibitor, 4-chloro-3-
hydroxyanthranilic acid (Enamine given daily from day 11–21,
125 mg/kg, i/p).
IDO Enzyme Assay
IDO activity was measured by high performance liquid
chromatography (HPLC) as described (13). Briefly, cells
were harvested, lysed (2 × freeze/thaw) and incubated in
substrate mixture (100mM potassium phosphate buffer pH =
6 containing 50 uM methylene blue, 50mM ascorbate, 0.4mM
L-Tryptophan, 20 ug catalase; all from Sigma) for 0 or 2 h
at 37◦C. Reaction was stopped and protein precipitated with
1:10 perchloric acid 60% (Sigma); samples were centrifuged,
filtered, and the kynurenine levels measured by HPLC. Results
are expressed as pmol of kynurenine ([2 h]-[0])/hour/mg
of protein.
FACS Staining
Splenocyte suspensions were stained in PBS with antibodies
against the surface markers CD11c (clone N418, eBioscience),
CD11b (clone M1/70, Biolegend), or CD19 (clone 1D3, BD
horizon), PD-L1 (clone 10F.9G2, BD horizon). After washing
with PBS, flow cytometric analyses were performed using a
Fortessa X20 cytometer (BD Biosciences), and data generated
were analyzed using FACSDiva (BD Biosciences) or FlowJo (Tree
Star, Ashland, OR) software. All antibody dilutions were used as
per manufacture’s instruction.
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Extraction of Kynurenine Pathway
Metabolites From Tissue Samples
Mouse brain/spleen tissue samples were suspended in ice-
cold 0.32M sucrose solution (∼500 µL solution/100mg
tissue) in sterile 2mL Eppendorf tubes. Tissue samples
were maintained on ice throughout the homogenization
protocol. Two homogenization beads were added to each
sample and the samples disrupted using a TissueLyser
instrument (Qiagen) for 2min at 25 shakes/second.
Homogenate samples were centrifuged at 13,000 rpm for
3min before the supernatant was transferred to a fresh
Eppendorf tube. Samples were centrifuged and transferred
again, as above. The total protein concentration in each
tissue homogenate sample was determined using a Pierce
BCA Protein Assay Kit, according to the manufacturer’s
protocol. Further adjustments to tissue homogenate
dilution/concentration were made using ice-cold 0.32M
sucrose solution.
Analysis of Kynurenine Pathway
Metabolites by Liquid
Chromatography-Tandem Mass
Spectrometry (LC-MS/MS)
Biological sample (100 µL; serum or diluted homogenate) were
diluted with 4% phosphoric acid (100 µL). A calibration curve
for each metabolite was prepared over ranges (0.05–100 ng) to
determine metabolite concentrations. Samples and calibration
standards were spiked with internal standard (d5-tryptophan)
and loaded onto individual wells of a Waters 96-well array HLB
solid phase extraction plate pre-conditioned with methanol (500
µL) and water (500 µL). Samples were washed with water (500
µL) and eluted with 70%methanol (200 µL). Reduced to dryness
and resuspended in 30% methanol (70 µL). Using a Shimadzu
Nexera UPLC system, 10 µL of each sample well was injected
(20 µL) onto an ACE C18-PFP (100mm × 2.1mm, 1.7µm,
ACT Technologies, Aberdeen, UK) coupled to an ABSciex
QTRAP 6500+ mass analyzer operated in polarity switching
electrospray mode. Flow rate was set at 0.5 mL/min at 40 ◦C.
A water:methanol gradient (both containing 0.1% formic acid)
was used for separation, with the following conditions: 90:10
water:methanol to 20:80 over 6min, followed by re-equilibration
to 80:20. The total run time was 9min. Analyst quantitation
software (ABI Sciex) was used to acquire and process the
data, following European Medicines Agency method validation
guidelines for accuracy, precision and limits of detection.
Statistical Analysis
Statistical significance for EAE clinical scores were evaluated with
two-way ANOVA, and normality checks were carried out on the
residuals which were approximately normally distributed. The
unpaired Student t-test was used for the remaining statistical
evaluations after normality was verified by the Shapiro-Wilk test.
Two-tailed p values < 0.05 were considered significant. Data
represent mean ± SEM. GraphPad Prism was used to perform
all data analyses.
FIGURE 1 | The DNA sensor cGAS mediates therapeutic responses to DNPs
that suppress EAE. (A) IDO activity in spleens from WT and cGAS-KO (KO)
mice treated with DNPs. (B) EAE was induced in B6 (WT) and cGAS-KO mice
(see section Materials and Methods), and EAE progression was monitored and
scored. Experimental groups (n = 10) were treated with DNPs (every other day
from day 11–21) and control WT mice were treated with vehicle (glucose 5%).
Data were analyzed by t-test for (A) and two-way ANOVA for (B). Experiments
were repeated once. NS, not significant; ***p < 0.001, #p < 0.0001.
Study Approval
All procedures were approved by the local Institutional Animal
Care and Use Committee in Augusta University and the UK
Home Office (Project license P1B4042BB).
RESULTS
Therapeutic Responses to DNPs Depend
on cGAS
As we reported previously, systemic (i/v) DNP administration
elevated IDO activity in many mouse tissues (9). DNPs did
not induce IDO activity in spleens from mice lacking the
cytosolic DNA sensor cGAS (Figure 1A). Consistent with this
finding, DNP treatment from EAE onset (11 days after MOG
immunization until day 21) had no significant effect on
EAE progression, while cGAS ablation had no effect on EAE
progression per se (Figure 1B). As expected, DNPs reduced
EAE clinical scores in B6 mice significantly until experimental
endpoints at day 25. Thus, DNP cargo DNA is sensed by cGAS to
induce tolerogenic responses that attenuate EAE progression.
Therapeutic Responses to STING Agonists
Depend on the PD-1/PD-L Pathway
The PD-1/PD-L pathway is required for tolerogenic DCs
expressing IDO1 to activate Foxp3-lineage regulatory CD4T
cells (Tregs), which then suppress effector T cell responses via
a mechanism dependent on PD-1/PD-L signaling (14, 15). To
test if the PD-1/PD-L pathway was required for therapeutic
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FIGURE 2 | Therapeutic responses to DNPs depend on the PD-1/PD-L pathway. (A–E) EAE was induced in B6 (WT), PD-1-KO (B,C), PD-L1-KO (D), and PD-L2-KO
(E) mice, and disease onset and progression was monitored and scored. At EAE onset (day 11) mice were treated with DNPs every other day until day 21 and control
mice were treated with vehicle (Vh; glucose 5%). Data were analyzed by two-way ANOVA (NS, not significant; *p < 0.05; ***p < 0.001, #p < 0.0001) and are
representative of 2 experiments with n = 6–18. (F) B6 (WT), PD-1-KO, PD-L1-KO, PD-L2-KO and PD-L1+L2-KO mice were treated with DNPs or Vh (glucose 5%).
Twenty-four hours later spleens were harvested and IDO activity in homogenized tissues was measured by assessing Kyn production ex vivo. Kyn levels were
significantly higher (p < 0.0001, n = 4–9, Student’s t-test) in spleens from all mice treated with DNPs regardless of their genotype, relative to Kyn levels in spleens
from vehicle-treated WT mice.
responses to DNPs, EAE was induced in mice lacking genes
encoding PD-1 or its ligands (PD-L1, PD-L2) and mice were
treated with DNPs at the time of EAE onset (Figure 2). Ablating
PD-1 or its ligands had no significant impact on the kinetics of
EAE induction or clinical severity, relative to WT control mice,
though EAE progression was slightly slower in PD-L2-KO mice
(Figure 2E). PD-1 ablation did not abolish therapeutic responses
to DNPs (Figure 2B) but EAE clinical severity was significantly
higher (scores 2–3) in DNP-treated PD-1-KO mice (Figure 2C),
relative to DNP-treated WT control mice (scores∼1). Moreover,
EAE severity in DNP-treated PD-1-KO mice was only slightly
lower than in vehicle-treated WT mice (scores 3–4). In contrast,
therapeutic responses to DNPs that slowed EAE progression
and reduced clinical severity were abolished in mice lacking
PD-L1 (Figure 2D), PD-L2 (Figure 2E) or both PD-1 ligands
(Supplemental Figure 1A). Thus, PD-L1 and PD-L2 have non-
redundant roles in mediating tolerogenic responses to DNPs that
alleviate EAE.
To test if PD-1/PD-L signaling was required to induce IDO1
in splenic DCs we assessed IDO enzyme activity in spleens of
naïve mice with defective PD-1/PD-L pathways 24 h after DNP
treatment. Following STING activation, induced IDO activity in
spleens ofWTmice andmice with defective PD-1/PD-L signaling
pathways was significantly higher than basal levels in untreated
mice, though induced IDO activity was slightly lower in the
absence of functional PD-1/PD-L signaling (Figure 2F). Thus,
therapeutic responses to DNP treatment were dependent on IDO
induction and PD-1/PD-L signaling but IDO1 induction was not
dependent on PD-1/PD-L signaling.
Cyclic 2′3′-guanyl-adenyl monophosphate (cGAMP) is a
potent natural STING agonist made when cGAS is activated
by DNA in mammalian cells (16). We tested if synthetic
cGAMP treatments incited tolerogenic responses that slow EAE
progression. cGAMP treatment from the time of EAE onset (days
11–21) reduced clinical scores significantly until experimental
endpoints at day 25 (Figure 3A). As for DNPs, therapeutic
responses to cGAMP were abolished in mice lacking PD-1
or PD-L1 genes (Figures 3B,C) or genes encoding both PD-1
ligands (Supplemental Figure 1B). In addition, IDO1 induction
in spleen was not dependent on PD-1/PD-L signaling after
cGAMP treatment to activate STING (Figure 3D).
DNPs Enhance PD-L1 Expression by
Splenic APCs
APCs expressing PD-L1 suppress effector T cell responses and
stabilize the regulatory functions of Foxp3 in Tregs via PD-1
(17, 18). As EAE induction alters APC phenotypes and numbers
we examined splenic APCs from mice treated with vehicle
(Vh, 5% glucose) or DNPs 22 days after MOG immunization.
DNP treatment stimulated splenic DCs (CD11c+) and myeloid
(CD11b+) cell subsets to up-regulate PD-L1 expression, while B
cells remained PD-L1neg (Figure 4). PD-L1 expression increased
uniformly on a small population of splenic DCs (CD11c+) co-
expressing the B cell marker CD19 (CD19+ DCs), which also
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FIGURE 3 | The PD-1/PD-L pathway is required for therapeutic responses to
cGAMP. (A–C) EAE was induced in B6 (WT), PD-1-KO, and PD-L1-KO mice,
and disease onset and progression was monitored and scored. At EAE onset
(day 11) mice were treated with cGAMP every other day until day 21 and
control mice were treated with vehicle (Vh; saline). Data were analyzed by
two-way ANOVA (NS, not significant; #p < 0.0001) and are representative of 2
experiments with n = 6–18. (D) Mice were treated with cGAMP or Vh (saline)
and 24 h later spleens were harvested and IDO activity in homogenized tissues
was measured by assessing Kyn production ex vivo. Data were analyzed using
Student’s t-test and Kyn levels were significantly higher in all mice (n = 4–9)
treated with cGAMP, B6 (WT, p < 0.001), PD-1-KO (p < 0.0001), PD-L1-KO
(p < 0.01), PD-L2-KO (p < 0.05) and PD-L1+L2-KO (p < 0.05) mice relative
to basal Kyn levels in vehicle-treated WT mice.
expanded following DNP treatment (Figure 4B). As reported
previously, CD19+ DCs exhibit hybrid features of both B
cells and DCs, and amongst splenic DC subsets, CD19+
DCs are uniquely competent to express IDO1 (19). PD-L1
expression also increased on a subset (∼50%) of conventional
(CD19neg) DCs, which also expanded after DNP treatment
(Figure 4C). In contrast, PD-L1 expression did not increase
on B cells, nor did B cells expand after DNP treatment
(Figure 4D). Myeloid (CD11b+) cells, as well as many CD11b+
and CD11bneg DCs, also expressed elevated PD-L1 and expanded
following DNP treatment (Figures 4F–H). DNP treatment did
not enhance MHCII levels significantly on APCs during EAE
(Supplemental Figure 2), though even in naïve mice CD19+
DCs expressed the highest levels of MHCII, consistent with the
mature APC status of this discrete DC subset (20). Thus, DNP
treatment promoted regulatory functions and expansion of DCs
but not B cells in mice with EAE.
Trp Depletion and AhR Signaling Are
Dispensable for Therapeutic Responses
After STING Activation
IDO activity depletes Trp to induce the integrated stress
response (ISR) driven by ribosomal GCN2 kinase, which shuts
down most protein synthesis but induces C/EBP homologous
protein (CHOP) expression (21). The ISR blocks effector T
cell responses, activates Tregs and suppresses pro-inflammatory
IL-6 production by plasmacytoid DCs (pDCs) to suppress
immunity (22, 23). Previous reports showed that GCN2 is not
required for EAE progression but is required for partial EAE
remission to manifest after peak disease (24, 25). We tested if
GCN2 and CHOP were required for therapeutic responses to
manifest after STING agonist treatments. Therapeutic responses
to cGAMPwere comparable inWT and GCN2-deficient (GCN2-
KO) mice (Supplemental Figure 3A), indicating that GCN2
is not essential for therapeutic responses following STING
activation to boost IDO activity. Therapeutic responses to
DNPs were also comparable in CHOP-KO and WT mice
(Supplemental Figure 3B). These outcomes indicate that GCN2
and CHOP are both dispensable for therapeutic responses
following STING activation.
Some Trp metabolites such as kynurenine (Kyn), suppress
immunity via AhR signaling (26, 27). Previous reports showed
that AhR gene ablation had minor or no significant effects on
EAE susceptibility, while treatments to block AhR signaling
suppressed EAE in WT mice (28–32). Prompted by this prior
work, we tested if AhR signaling mediated therapeutic responses
to STING agonists. Mice were given the AhR antagonist drug
CH223191 (CH) at optimal doses (5 mg/kg) shown to block
AhR signaling effectively in mice (30, 33–35). CH treatments
were administered daily from EAE onset (day 11). Therapeutic
responses to cGAMPwere comparable in the presence or absence
of CH co-treatments (Supplemental Figure 3C), suggesting that
AhR signaling is dispensable for therapeutic responses induced
by cGAMP.
Manipulating Trp Catabolism Potentiates
Therapeutic Responses to DNPs
In addition to immunosuppressive Trp metabolites, cells
expressing IDO1 may produce neuroactive Trp metabolites
that exacerbate comorbidities such as pain, depression, and
fatigue in patients with MS and other neuroinflammatory
syndromes (36–38). Quinolinic acid (QA) is a N-methyl-D-
aspartate (NMDA) receptor agonist and sustained production of
neuro-excitatory QA in the central nervous system (CNS) causes
neuronal injury. Another Trp catabolite, kynurenic acid (KA),
antagonizes NMDA receptor signaling and the KA:QA balance
is a pivotal factor modulating neurologic comorbidities (39).
Since increased IDO activity may have neurologic consequences
such as increased nociception (40), we examined how drugs that
block production of neuroactive QA or KA impact therapeutic
responses to DNPs in the EAE model. As depicted in Figure 5A,
kynurenine aminotransferase-II (KatII) converts Kyn into KA
and 3-hydroxyanthranilic acid (HAA) dioxygenase (HAAO)
converts HAA into QA. The KatII inhibitor PF-04859989 (PF)
had no significant impact on EAE progression or clinical
severity when applied at EAE onset (Figure 5B). Remarkably,
when combined PF and DNP treatments were administered at
EAE onset most mice showed no symptoms of EAE (mean
score <0.2) during or after treatments (Figure 5B). Therapeutic
responses to combined PF and DNPs were significantly better
than responses to DNPs (mean score 1). Thus, PF and DNP
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FIGURE 4 | DNPs enhance maturation and expansion of tolerogenic APCs expressing PD-L1. EAE was induced in B6 (WT), and experimental groups were treated
with either DNP or its vehicle (Veh; 5% glucose) from day 11–21, every other day. On day 22 splenocytes were harvested and stained for CD11c, CD11b, CD19, and
PDL1, and analyzed by flow cytometry. Gating strategy and percentages of the populations (A,E) analyzed for PDL1. Percentages of different populations of DCs and
monocytes expressing PDL1 and the levels of PDL1 expression are shown (B–D,F–H). Statistical significance was determined by two tailed unpaired Student’s t-test;
NS, not significant; *p < 0.05; **p < 0.01.
co-treatments suppressed EAE progression in the majority of
mice, with mild symptoms persisting in only a few mice in this
group. Similar outcomes were observed in mice co-treated with
an HAAO inhibitor, 4-chloro-3-hydroxyanthranilic acid (4Cl-
HAA), though 4Cl-HAA monotherapy slowed EAE progression
significantly but did not prevent EAE progression (Figure 5C).
Thus, KatII inhibition synergized with DNP treatments while
HAAO inhibition supplemented therapeutic responses to DNPs
to suppress EAE progression. Thus, STING activation to boost
IDO activity in the presence of KatII or HAAO inhibitors are
effective strategies to suppress EAE progression.
Targeted metabolomics (LC-MS/MS) analyses (41, 42) of
brain tissues taken at peak EAE severity (day 14, 3 h
after final treatments) revealed that DNP treatments boosted
brain Kyn, relative to levels in mice with EAE, and that
increased brain Kyn correlated with reduced EAE severity
(Supplemental Figure 4A). Elevated Kyn was also detected in
spleen and serum of DNP-treated mice with EAE (data not
shown) confirming that DNPs boost IDO activity systemically.
However, DNP treatments reduced brain IDO expression
in neurons of MOG-immunized mice (10), suggesting that
increased brain Kyn in DNP-treated mice may be generated
in non-CNS tissues and crosses the blood-brain barrier.
DNP treatments reduced brain 3HAA levels significantly
(Supplemental Figure 4B) and boosted brain 3HK levels, albeit
not significantly (Supplemental Figure 4C), while brain KA
levels were unaffected by EAE induction or DNP treatments
(Supplemental Figure 4D). Co-treatment with KatII inhibitor
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FIGURE 5 | Manipulating the IDO pathway reinforces therapeutic responses to
DNP treatments. (A) The kynurenine pathway. (B,C) B6 (WT) mice were
treated with DNPs or Vh (glucose 5%), as described previously. Other groups
received DNPs and drugs that inhibit KatII (B; PF-04859989 daily from day
11–22, 40 mg/kg, i/p), or HAAO (C; 4-chloro-3-hydroxyanthranilic acid daily
from day 11–21, 125 mg/kg, i/p). Mice were monitored and EAE clinical scores
were recorded. Data were analyzed by two-way ANOVA. Experiments were
repeated once (n = 8–10). NS, not significant; *p < 0.05; **p < 0.01; #p <
0.0001.
(PF) blocked DNP-induced increase in brain Kyn, while brain
Kyn levels were still elevated in mice co-treated with HAAO
inhibitor (4Cl-HAA) and DNPs (Supplemental Figure 4A).
Further analyses of metabolomics data provided no fresh insights
into underlying metabolic processes that explain substantial
differences in EAE severity in distinct treatment groups.
DISCUSSION
Previously, we showed that DNPs and a bacterial CDN,
cyclic diguanyl monophosphate (cdiGMP), activated STING to
enhance IDO-dependent regulatory functions of splenic DCs
and suppress antigen induced arthritis (AIA) and EAE in mice
(9, 10, 12). In this study, we further dissect critical pathway
components that promote therapeutic responses to STING
agonists in the EAE model and show that drugs targeting KatII
or HAAO reinforce therapeutic responses to DNPs to suppress
EAE progression.
The finding that the cytosolic DNA sensor cGAS promotes
therapeutic responses and is required to induce IDO after DNP
treatment reveals that cGAS senses DNP cargo DNA to activate
STING/IFN-I signaling in DCs competent to express IDO
and suppress autoimmunity. STING also promoted tolerogenic
responses that attenuated autoimmune lupus progression in
susceptible MRLlpr mice, suggesting that cytosolic DNA sensors
promote tolerogenic responses that slow lupus progression in
this model (7), though specific requirements for cGAS or IDO
to promote tolerogenic responses were not addressed in this
study. STING agonists also induced tolerogenic responses that
promoted Lewis Lung Carcinoma (LLC) growth in mice by
stimulating IDO activity in inflamed lymph nodes draining sites
of tumor growth, though cGAS was not essential to induce
IDO1 in the LLC model (8). In contrast, STING agonists incited
potent anti-tumor responses in mice bearing more immunogenic
B16 melanomas (4). Opposing outcomes in distinct tumor
models emphasize that STING signaling may stimulate or
suppress immunity. Elevated IDO activity is a common immune
checkpoint in cancer (43), reinforcing the paradigm that boosting
IDO activity protects inflamed tissues from immune-mediated
destruction. On the other hand, cytosolic DNA sensing by cGAS
to activate STING incited anti-viral immunity, spontaneous
autoimmunity in mice with defective DNA catabolizing enzymes
and anti-tumor immunity (44–48). How DNA from cellular,
microbial or artificial sources incites diametric tolerogenic or
immunogenic responses is unclear. Differential DNA uptake
and sensing by distinct cell types in different tissues may be
key factors driving diametric immune responses to DNA in
different inflammatory settings. Sustained tissue re-modeling and
local inflammation enhance cell death and dying cells promote
potent tolerogenic responses, in part because DNA from dying
cells is sensed to induce IDO1 and suppress immunity and
autoimmunity (12, 49, 50). Intra-tumoral injection of synthetic
CDNs was essential to incite robust anti-tumor responses
to immunogenic B16 melanomas (4). In contrast, systemic
administration of STING agonists was necessary to induce
tolerogenic responses (9, 10, 12). These findings suggest that
circulating STING agonists and dying cells are sensed to induce
tolerogenic processes that protect tissues from immune-mediated
attack, while DNA sensing to activate STING in inflamed
tissues may incite immunogenic or tolerogenic responses that
protect against infections or promote tumor growth, respectively.
Previously, we identified splenic myeloid (CD11b+) DCs as
cells uniquely competent to incite IDO1-dependent tolerogenic
responses by ingesting and sensing DNP cargo DNA or CDNs
to activate STING/IFN-I signaling and induce specialized splenic
DCs to express IDO1 (12). Thus, splenic myeloid DCs may be
pivotal cells that sense ingested DNA and cGAMP to generate
robust tolerogenic responses that prevent EAE progression.
PD-1/PD-L signaling drives potent tolerogenic responses that
suppress effector T cells and activate Tregs in multiple settings
(51). Therapeutic responses to DNPs in the EAE model were
partially dependent on PD-1 and fully dependent on PD-L1 and
PD-L2, respectively, while therapeutic responses to cGAMP were
abolished in mice lacking PD-1 or PD-L1. It is unclear how PD-1
independent therapeutic responses to DNPs manifest but DNPs
contain the cationic polymer polyethylenimine that stimulates
innate immune signaling via TLR5 (52), while cGAMP targets
STING only. STING agonist treatments enhanced the numbers
of splenic DCs (CD11c+) andmyeloid (CD11b+) cells expressing
PD-L1 and PD-L1 levels expressed by these cells, suggesting that
DCs and myeloid antigen presenting cells (APCs) suppress T
cell responses driving EAE. Potential roles for autoreactive B
cells in MS immunopathology have been proposed because B cell
depleting anti-CD19 mAbs alleviated MS in some patients (53).
Discrete B cell subsets also promote or regulate EAE in mice
(54, 55). In mice, a discrete subset of marginal zone DCs co-
expressing the B cell marker CD19 (CD19+ DCs) are uniquely
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competent to express IDO1 and become potent regulatory APCs
(19). CD19+ DCs expressing IDO1 suppress T cell responses
and activate Tregs to block their conversion into TH17 T cells.
Phenotypic overlaps between CD19+ DCs and B cells may
explain why some ‘B cell’ subsets regulate EAE. CD19+ DCs
expressing IDO1 also expanded in spleens of aged lupus-prone
Nba2 mice and during chronic retroviral infections in mice
(40, 56). Thus, regulatory B cell subsets, CD19+ DCs expressing
IDO1 and other regulatory APCs may contribute to therapeutic
responses to STING agonists that suppress EAE.
Defects in PD-1/PD-L signaling did not compromise IDO1
induction following STING activation, indicating that the PD-
1/PD-L and IDO1 pathways act independently to promote
tolerogenic responses in response to STING activation. In
contrast, PD-1 signaling was essential to induce IDO1 and
tolerogenic responses following TLR9 ligation (15). Like STING
agonists, TLR9 ligands stimulate IFN-I production by DCs
and IFN-I induces IDO (17, 19). Ablating CD19 or the PD-
1/PD-L pathway abolished IDO induction in CD19+ DCs
and tolerogenic responses following TLR9 ligation and instead
elicited immunogenic responses. Thus, CD19+ DCs are pivotal
cells controlling responses to TLR9 ligands and PD-1/PD-L
interactions between Tregs (or T cells) and CD19+ DCs are
necessary to induce CD19+ DCs to express IDO1 and acquire
tolerogenic phenotypes in this setting. As IDO induction after
STING activation was not PD-1/PD-L dependent, signals from
Tregs or T cells expressing PD-1 to induce CD19+ DCs to
express IDO1 are not required for tolerogenic responses to
STING agonists. It is unclear why PD-1/PD-L interactions
were not required to induce IDO1 in CD19+ DCs following
STING activation. However, downstream interactions between
regulatory APCs or other cells types expressing PD-1 ligands
and T cells or Tregs expressing PD-1 are essential to promote
tolerogenic responses that suppress EAE.
IDO activity inhibits T cell responses via two metabolic
pathways, Trp depletion to activate the GCN2/CHOP-dependent
ISR and Trp catabolite production (11, 57). HAA suppresses T
cell responses by inhibiting PDK1-mediated NF-kB activation to
promote T cell apoptosis (58), while Kyn and KA are natural
AhR ligands and AhR signaling regulates T cell responses (26,
27, 59). Therapeutic responses to DNPs were unaffected by
GCN2 ablation while therapeutic responses to cGAMP were
unaffected by AhR signaling blockade, indicating that neither
pathway is essential for therapeutic responses to STING agonists.
Also, CHOP ablation had no major impact on therapeutic
responses to DNPs. Though CHOP is a GCN2 target, other stress
pathways can activate CHOP and these alternative pathways
may mediate therapeutic effects. The ISR and AhR signaling
may be dispensable for therapeutic responses to STING agonists
because each pathway compensates for loss of the other making
each pathway functionally redundant for therapeutic responses.
Alternatively, other metabolic effects of elevated IDO activity
such as altered redox potentials (60) may influence EAE
pathogenesis and therapeutic responses to STING agonists.
Two well-characterized and well-tolerated drugs that inhibit
KatII (61–63) or HAAO (64–66) were used to assess metabolic
requirements that promote therapeutic responses to DNPs
downstream of IDO. Combining either drug with DNPs
prevented EAE progression, even after treatments ended. Stable
disease control is difficult to achieve in the EAE model, as
depots of autoantigen and adjuvant (MOG/CFA) with potent
encephalitogenic properties persist at sites of immunization. As
KatII converts Kyn into KA and HAAO converts HAA into QA
(Figure 5A), our findings suggest that KatII and HAAO activity
may attenuate therapeutic responses to DNPs by consuming
Trp metabolites that mediate immune suppression such as Kyn,
3-HK and HAA. Previous studies showed that HAA (or a
synthetic HAA derivative) attenuated EAE, though therapeutic
responses were weak (67, 68). Thus, boosting HAA production
and blocking HAA consumption in tissues may be more
effective than administering exogenousHAA. Reduced KA orQA
production may also contribute to robust therapeutic responses
after DNP treatment. HAAO inhibitionmay attenuate neurologic
comorbidities by reducing production of neuroexcitatory QA,
though blocking KA production may potentiate neurologic
comorbidities since KA antagonizes QA-mediated neuronal
stimulation via NMDA. To further evaluate metabolic changes
in the Kyn pathway we conducted metabolomics analyses of
tissues (brain, spleen) and serum samples. Outcomes confirmed
that DNPs boost IDO activity systemically and suggest that Kyn
generated in non-CNS tissues following DNP treatment may
cross the blood-brain barrier in DNP-treated mice. However, no
additional insights were forthcoming, highlighting the technical
difficulty of identifying critical metabolic changes in small
FIGURE 6 | Graphical hypothesis. MOG immunization generates
MOG-specific effector T cells that migrate to the CNS where they cause
neuronal injury and induce neurons to express IDO1 and produce neurotoxic
Trp catabolites such as QA (green highlights). STING agonists induce DCs in
lymphoid tissues to express IDO1 and produce Trp catabolites that suppress
generation of MOG-specific T cells (red highlights). Manipulating Trp
catabolism to enhance production of immune suppressive catabolites and
block production of neurotoxic catabolites may be an effective strategy to
boost tolerogenic responses that promote stable EAE remission and alleviate
neurologic comorbidities.
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cohorts of physiologic cells that drive therapeutic responses
using metabolomics analyses. These points notwithstanding,
our findings show that boosting kinetic flux through the
Kyn pathway and manipulating the balance of alternative Trp
metabolism pathways downstream of IDO have profound effects
on immunologic responses to STING agonists that promote
durable therapeutic responses in the EAE model.
Abnormal levels of KA and QA were detected in serum of MS
patients and abnormalities in Kyn pathway metabolism may be
associated with clinical MS subtypes, and may serve as potential
biomarkers of MS stage and progression (38, 69, 70). As we
depict in the graphic hypothesis (Figure 6) summarizing findings
reported here, and in a previous study using the same model
(10), the Kyn pathway has a complex role in immunologic and
neurologic processes driving autoimmunity and comorbidities
during EAE disease progression and responses to STING
agonist treatments to alleviate EAE. Sustained IDO expression
in CNS tissues contributes to EAE pathogenesis because Trp
metabolites such as QA may cause neuro-inflammatory injury
leading to psychotic disorders (71). Previously, we reported
that EAE induction per se stimulates IDO1 expression by CNS
neurons, whichmay promote neuronal injury (10). Paradoxically,
DNP treatments abolished IDO expression in CNS neurons,
possibly because increased IDO activity in lymphoid tissues
blocked expansion and activation of MOG-specific T cells
that would otherwise infiltrate CNS tissues and induce local
IDO expression, for example by secreting IFNγ. Several Trp
metabolites, including Kyn, KA, 3-HK and HAA, have been
implicated in immune regulation as they diminish TCR signaling
and enhance AhR signaling in T cells and other immune
cells (27, 72). The Trp catabolite xanthurenic acid (XA) may
also suppress T cell responses after DNP treatment, as XA
inhibits synthesis of the enzyme cofactor tetrahydrobiopterin
(BH4) by activated T cells and BH4 is essential for T cell
clonal expansion (73). Another mechanism that may promote
therapeutic responses to STING agonists is that HAA induces
CNS astrocytes to express HO-1, which generates compounds
with anti-inflammatory and cytoprotective properties (74).
Further studies to identify specific cell types that produce
and consume particular Trp metabolites, determine the tissue
locations of such cells and define targets of Trp metabolites will
be key to understanding how increased metabolic flux through
the Kyn pathway contributes to immunologic and neurologic
processes during disease progression and comorbidities, as well
as responses to therapy. In summary, our findings reveal that
boosting IDO activity and manipulating the IDO pathway is
an effective therapeutic strategy to treat neuro-inflammatory
autoimmune syndromes.
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